Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke

Safety and Efficacy of Intensive vs. Guideline Antiplatelet Therapy in High-Risk Patients with Recent Ischemic Stroke or Transient Ischemic Attack: Rationale and Design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) Trial (ISRCTN47823388)

(2015)   International Journal of Stroke

Tissue Factor and Atherothrombosis

(2015) Kohei Tatsumi et al.   Journal of Atherosclerosis and Thrombosis

A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons

(2015) Deanna G. Brown et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Idarucizumab for Dabigatran Reversal

(2015) Charles V. Pollack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis

(2014) Michelle A.H. Sonneveld et al.   BLOOD REVIEWS

Warfarin Versus Novel Oral Anticoagulants

(2014) Rishi K. Wadhera et al.   CIRCULATION

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor

(2014) Henri Bounameaux et al.   DRUGS

Statistical Analysis Plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) Trial

(2014) Philip M. W. Bath et al.   International Journal of Stroke

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

(2014) Walter N. Kernan et al.   STROKE

Meta-Analysis of Rivaroxaban and Bleeding Risk

(2013) Guila Wasserlauf et al.   AMERICAN JOURNAL OF CARDIOLOGY

The Effectiveness of Dual Antiplatelet Treatment in Acute Ischemic Stroke Patients with Intracranial Arterial Stenosis: A Subgroup Analysis of CLAIR Study

(2013) Xin Wang et al.   International Journal of Stroke

A practical approach to minimize the interaction of dietary vitamin K with warfarin

(2013) C.-H. Chang et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations

(2013) L. Tóth et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack

(2013) Yongjun Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

(2012) Charles Frost et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Antiplatelet Drugs

(2012) John W. Eikelboom et al.   CHEST

Evidence-Based Management of Anticoagulant Therapy

(2012) Anne Holbrook et al.   CHEST

Oral Direct Factor Xa Inhibitors

(2012) Calvin H. Yeh et al.   CIRCULATION RESEARCH

Antiplatelet Therapy

(2012) Afshin A. Divani et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Aspirin Resistance in Chinese Stroke Patients Increased the Rate of Recurrent Stroke and other Vascular Events

(2012) Xingyang Yi et al.   International Journal of Stroke

Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm

(2012) Shunichi Homma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin

(2012) Nikolaos Patsopoulos et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Clopidogrel and proton pump inhibitors - where do we stand in 2012?

(2012) Michael D Drepper   WORLD JOURNAL OF GASTROENTEROLOGY

Direct Diagnosis is Superior to Risk Factor Prediction Tools for Management of Vessel Wall Disease

(2012) Afshin A. Divani et al.   Frontiers in Neurology

Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events

(2011) Robert Guthrie   ADVANCES IN THERAPY

Dabigatran etexilate: A novel oral direct thrombin inhibitor

(2011) M. L. Blommel et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Direct thrombin inhibitors

(2011) Catherine J. Lee et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary

(2011) Thomas G. Brott et al.   CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS

Dabigatran Etexilate

(2011) Graeme J. Hankey et al.   CIRCULATION

Novel roles of cAMP/cGMP-dependent signaling in platelets

(2011) A. SMOLENSKI   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor

(2011) Pancras C. Wong et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran

(2011) B. Nhi Beasley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis

(2011) Marc I. Chimowitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adenosine and blood platelets

(2011) Hillary A. Johnston-Cox et al.   Purinergic Signalling

Entering the Era of Non-Basic P1 Site Groups: Discovery of Xarelto™ (Rivaroxaban)

(2010) Alexander Straub et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

(2010) Koichiro Ogata et al.   JOURNAL OF CLINICAL PHARMACOLOGY

What Is the Future of Stroke Prevention?: Debate: Polypill Versus Personalized Risk Factor Modification

(2010) W. N. Kernan et al.   STROKE

Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack

(2010) Karen L. Furie et al.   STROKE

The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants

(2010) Meyer Michel Samama   THROMBOSIS RESEARCH

The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease

(2009) M. Wurtz et al.   HEART

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

(2009) Gilles Montalescot et al.   LANCET

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

(2008) Bengt I Eriksson et al.   CLINICAL PHARMACOKINETICS

Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke

(2008) Ralph L. Sacco et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of Thrombus Formation

(2008) Bruce Furie et al.   NEW ENGLAND JOURNAL OF MEDICINE